Examination of nighttime sleep-related problems during double-blind, placebo-controlled trials of galantamine in patients with Alzheimer's disease

References

• Chokroverty S. Sleep disorders in elderly persons. In: Chokroverty S, editors. Sleep disorders medicine: basic science, technical considerations, and clinical aspects. Boston: Butterworth-Heinemann; 1994. p. 401–15
   Google Scholar
• Bliwise DL, Tinklenberg JR, Yesavage JA. Timing of sleep and wakefulness in Alzheimer’s disease patients at home. Biol Psychiatry 1992;31:1163–5
   Google Scholar
• McCurry SM, Logsdon RG, Teri L, et al. Characteristics of sleep disturbance in community-dwelling Alzheimer disease patients. J Geriat Psychiat Neurol 1999;12:53–9
   PubMed Web of Science ®Google Scholar
• Moe KE, Vitiello MV, Larsen LH, Prinz PN. Symposium: cognitive processes and sleep disturbances: sleep/wake patterns in Alzheimer’s disease: relationships with cognition and function. J Sleep Res 1995;4:15–20
   PubMed Web of Science ®Google Scholar
• Reynolds CF 3rd, Kupfer DJ, Taska LS, et al. EEG sleep in elderly depressed, demented, and healthy subjects. Biol Psychiatry 1985;20:431–42
   PubMed Web of Science ®Google Scholar
• Vitiello MV, Boroson S. Sleep disturbances in patients with Alzheimer’s disease: epidemiology, pathophysiology and treatment. CNS Drugs 2001;15:777–96
   PubMed Web of Science ®Google Scholar
• Donaldson C, Tarrier N, Burns A. Determinants of carer stress in Alzheimer’s disease. Int J Geriat Psychiatry 1998;13:248–56
   Google Scholar
• Gaugler JE, Edwards AB, Femia EE, et al. Predictors of institutionalization of cognitively impaired elders: family help and the timing of placement. J Gerontol B Psychol Sci Soc Sci 2000;55:247–55
   PubMed Web of Science ®Google Scholar
• Hope T, Keene J, Gedling K, et al. Predictors of institutionalization for people with dementia living at home with a carer. Int J Geriatr Psychiatry 1998;13:682–90
   PubMed Web of Science ®Google Scholar
• Pollak CP, Perlick D. Sleep problems and institutionalization of the elderly. J Geriat Psychiatry Neurol 1991;4:204–10
   PubMedGoogle Scholar
• Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003;60: 1119–22
   Google Scholar
• Wimo A, Winblad B, Aguero-Torres H, von Strauss E. The magnitude of dementia occurrence in the world. Alzheimer Disease and Associated Disorders 2003;17(2):63–7
   PubMed Web of Science ®Google Scholar
• Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer’s disease – results from a multinational trial. Dement Geriat Cogn Disord 1999;10:237–44
   PubMed Web of Science ®Google Scholar
• Rogers SL, Doody RS, Mohs RC, Friedhoff LT, Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo–controlled study. Arch Intern Med 1998;158: 1021–31
   Google Scholar
• Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology 1998;50: 136–45
   Google Scholar
• Wilkinson D, Passmore P, Potocnik F, Maud C, Hock C. Donepezil compared with rivastigmine in Alzheimer’s disease: similar efficacy but better tolerability, and physician and caregiver satisfaction in a multinational randomized trial. Poster presentation at the 14th Annual Meeting of the American Association of Geriatric Psychiatry, 23–26 February 2001, San Francisco, CA.
   Google Scholar
• Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriat Psychiatry 1998;1: 55–65
   Google Scholar
• Raskind MA, Peskind ER, Wessel T, Yuan W, Galantamine USA-1 Study Group. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000;54: 2261–8
   Google Scholar
• Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomized controlled trial. BMJ 1999;318:633–8
   Google Scholar
• Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine. Neurology 2000;54:2269–76
   PubMed Web of Science ®Google Scholar
• Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomized controlled trial. BMJ 2000;321:1445–9
   Google Scholar
• Koella WP. The organization and regulation of sleep. A review of the experimental evidence and a novel integrated model of the organizing and regulating apparatus. Experientia 1984;40:309–38
   Google Scholar
• Seifrietz E, Gillin JC, Rapaport MH, Kelsoe JR, Bhatti T, Stahl S. Sleep electroencephalo-graphic response to muscarinic and serotonin1A receptor probes in patients with major depression and in normal controls. Biol Psychiatry 1998;44:21–33
   PubMed Web of Science ®Google Scholar
• de Jesus Cabeza R, Zoltoski RK, Gillin JC. Biochemical pharmacology of sleep. In: Chokroverty S, editor. Sleep disorders medicine: basic science, technical considerations, and clinical aspects, 2nd ed. Boston: Butterworth-Heinemann; 1999. p. 37–55
   Google Scholar
• Sitaram N, Gillin JC. Development and use of pharmacological probes of the CNS in man: evidence of cholinergic abnormality in primary affective illness. Biol Psychiatry 1980;15:925–55
   PubMed Web of Science ®Google Scholar
• Ross JS, Shua-Haim JR. Aricept-induced nightmares in Alzheimer’s disease: 2 case reports. J Am Geriat Soc 1998;46:119–20
   PubMed Web of Science ®Google Scholar
• Folstein MF, Folstein SE, McHugh PR. ‘Mini-Mental State:’ a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–98
   Google Scholar
• Friedman L, Furberg CD, DeMets DL. 1985. Fundamentals of clinical trials, 2nd ed. Littleton (MA): PSG Publishing Company, Inc.; 1985
   Google Scholar
• Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D. Effects of a flexible galantamine dose in Alzheimer’s disease: a randomized, controlled trial. J Neurol Neurosurg Psychiatry 2001;71:589–95
   Google Scholar
• Buysse DJ, Reynolds III CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193–213
   PubMed Web of Science ®Google Scholar
• Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44: 2308–14
   Google Scholar
• Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 1997;48(Suppl 6):S10–S16
   Google Scholar
• Markowitz JS, Gutterman EM, Lilienfeld S, Papadopoulos, G. Sleep-related outcomes in persons with mild to moderate Alzheimer’s disease in a placebo-controlled trial of galantamine. Sleep 2003;26(5):602–6
   Google Scholar
• Inglis F, The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int J Clin Pract Suppl 2002: 45–63
   PubMedGoogle Scholar
• Stahl SM, Markowitz JS, Gutterman E, Papadopoulos G. Co-use of donepezil and hypnotics among Alzheimer’s disease patients living in the community. J Clin Psychiatry 2003;64:466–72
   PubMed Web of Science ®Google Scholar
• Robillard A, McKelvey R, Nasreddine Z. Galantamine improves quality of sleep in patients previously treated with donepezil (preliminary results). Poster presented at the 14th Annual Meeting of the American Association of Geriatric Psychiatry, 23–26 February 2001, San Francisco, CA
   Google Scholar
• Cummings JL. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry 2000;157:4–15
   PubMed Web of Science ®Google Scholar
• Samochocki M, Zerlin M, Jostock R, et al. Galantamine is an allosterically potentiating ligand of the human a4/b2 nAChR. Acta Neurol Scand 2000;176(Suppl):68–73
   Google Scholar
• Stahl SM. The new cholinesterase inhibitors for Alzheimer’s disease, part 1: their similarities are different. J Clin Psychiat 2000:61:710–1
   PubMed Web of Science ®Google Scholar
• Stahl SM. The new cholinesterase inhibitors for Alzheimer’s disease, part 2: illustrating their mechanisms of action. J Clin Psychiat 2000:61:813–4
   PubMed Web of Science ®Google Scholar